Gilead Sciences has announced an update on its ongoing clinical study evaluating an alternative dosing schedule for sacituzumab govitecan-hziy (SG) in treating advanced triple-negative breast cancer (TNBC). The Phase 1/2, open-label study aims to assess the safety, tolerability, and effectiveness of SG, with a focus on improving objective response rates and progression-free survival. The study began on April 30, 2025, and is currently recruiting participants. The latest update was submitted on August 8, 2025, indicating continued progress. Successful outcomes could positively impact Gilead Sciences' stock performance and strengthen its position in the oncology market.

Gilead Sciences reported stronger-than-expected financial results for its second quarter of 2025, with revenue of $7.08 billion, a 1.8% increase from the previous year, and net income of $1.96 billion, up 21% year-over-year. The company's profit margin improved to 28% from 23% in the prior quarter, and earnings per share rose to $1.57 from $1.29. Revenue outperformed analyst estimates by 1.7%, and EPS exceeded expectations by 5.0%. Analysts project average annual revenue growth of 4.0% over the next three years, compared to a 19% industry-wide growth forecast for U.S. biotech firms. The company's stock rose 5.5% from the previous week.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gilead Sciences' lenacapavir, a twice-yearly injectable HIV prevention drug, for use in the EU. If approved, it would become the first HIV prevention medicine in Europe not administered daily, weekly, or monthly. The drug, marketed as Yeytuo, is intended as pre-exposure prophylaxis (PrEP) for adults and adolescents at high risk of HIV-1 infection. The recommendation is based on data from two Phase III trials, PURPOSE 1 and PURPOSE 2. A similar version, Yeztugo, was previously approved by the U.S. FDA in June 2025. The WHO estimates that 1.3 million new HIV infections occurred globally in 2024.

Gilead Sciences has discontinued two drug candidates, cilofexor and firsocostat, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a liver disease linked to fatty liver. The candidates were part of a joint development program with Novo Nordisk, which includes Novo Nordisk's semaglutide, the active ingredient in Ozempic. Gilead has decided to halt the combination therapy development despite prior collaboration.

Global stock markets showed mixed performance as investors awaited a U.S. inflation report and the potential extension of a 90-day pause on proposed triple-digit tariffs between the U.S. and China. The S&P 500 remained near its record high, while the Dow rose slightly and the Nasdaq dipped slightly. European and Asian markets were generally stable or slightly positive, with notable gains in Hong Kong and Taiwan. Analysts noted that U.S. semiconductor companies like Nvidia and AMD are under scrutiny due to potential revenue-sharing agreements with the U.S. government for sales to China. Gilead Sciences and Expedia Group reported strong financial results, boosting their stock prices. Paramount Skydance shares fell sharply after its formation, while Warner Bros. Discovery declined. Markets remain focused on inflation data, trade policy developments, and their potential impact on interest rates and economic growth.